Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical DevelopmentMagdalena Ślusarczyk, Christopher McGuigan, Monica Huerta Lopez et al.|Journal of Medicinal Chemistry|2014Cited by 151
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple SclerosisJannis Müller, Tomáš Kalinčík, Sifat Sharmin et al.|JAMA Neurology|2025Cited by 43
Abstract B46: NUC-3373: A novel pyrimidine nucleotide analogue that overcomes key cancer drug resistance limiting patient survivalEssam Ghazaly, Sarah P. Blagden, Magdalena Ślusarczyk et al.|Molecular Cancer Therapeutics|2015Cited by 9
ProGem1: Phase I first-in-human study of the novel nucleotide NUC-1031 in adult patients with advanced solid tumors.Essam Ghazaly, Sarah P. Blagden, Robert Leonard et al.|Journal of Clinical Oncology|2013Cited by 8
Final results of ProGem1, the first in-human phase I/II study of NUC-1031 in patients with solid malignancies.Sarah P. Blagden, Christopher McGuigan, Ivana Rizzuto et al.|Journal of Clinical Oncology|2015Cited by 7